{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Chimerism at day 100"},{"measurements":[{"comment":"Data not available due to patient's death","groupId":"OG000","value":"NA"}],"title":"Chimerism at 6 months"},{"measurements":[{"comment":"Data not available due to patient's death","groupId":"OG000","value":"NA"}],"title":"Chimerism at 1 year"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"Number of patients with chimerism at day 100, 6 months and 1 year","groups":[{"description":"This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen. This regimen consists of fludarabine, cyclophosphamide and low dose total body irradiation (TBI).\n\nFludarabine: Fludarabine 30 mg/m2 IV over 30-60 minutes on days -6 through -2 before transplant.\n\nCyclophosphamide: Cyclophosphamide 14.5 mg/kg IV over 1-2 hours on days -6 and -5 before transplant and Cyclophosphamide 50 mg/kg IV on days 3 and 4 post-transplant.\n\nTotal Body Irradiation: TBI 200cGy on day -1 before transplant.\n\nHaploidentical stem cell transplant: Non-T-cell depleted bone marrow infusion","id":"OG000","title":"Haploidentical Stem Cell Transplant"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Chimerism at 6 months and 1 year not evaluated","reportingStatus":"POSTED","timeFrame":"100 days","title":"Number of Patients With Chimerism","type":"SECONDARY","unitOfMeasure":"Participants"}